Control of octreotide release from silk fibroin microspheres

Publication date: September 2019Source: Materials Science and Engineering: C, Volume 102Author(s): He Gong, Jing Wang, Jue Zhang, Jianbing Wu, Zhaozhu Zheng, Xusheng Xie, David L. Kaplan, Gang Li, Xiaoqin WangAbstractPoly(d,l-lactide-co-glycolide) (PLGA) microspheres have been used as an injectable depot for prolonged release of octreotide (Sandostatin LAR®), a peptide drug for the treatment of acromegaly and gastrointestinal tumors. However, acylation and incomplete release of the encapsulated octreotide, as well as acidic degradation product-induced inflammation are the major challenges hampering widespread clinical applications of this delivery system. The purpose of this study was to develop a novel octreotide-delivering system utilizing naturally derived biodegradable material, silk fibroin (SF). Octreotide acetate was encapsulated in the SF microspheres with a high loading (8–10 wt%) using polyethylene glycol (PEG)-assisted emulsification method. The octreotide-SF microspheres exhibited a silk I structure (low crystallinity) and burst release in in vitro release studies. Ethanol treatment after microsphere formation significantly increased β-sheet and silk II structure (high crystallinity) of the microspheres, significantly reducing the burst release and resulting in zero-order sustained release of octreotide over 102 days, and the data could be fit to the diffusion-driven release model. After the ethanol-treated microspheres were intramuscularly inje...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research

Related Links:

Acromegaly results in a significantly increased morbidity and mortality due to cardiovascular and respiratory complications as well as malignancies arising mainly from the colon. Furthermore, an increased lifetime risk of malignant transformation of pre-malignant colonic lesions relates to a worse overall prognosis from colorectal cancer, which is currently considered a major disease related complication. In this review we provide some insight into colonic changes in this condition, summarise current knowledge and evidence on the use of colonoscopic screening in patients with acromegaly, and suggest a recommended screening protocol.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
AbstractPurposeThe increased life expectancy in the general population is causing rapid growth of the number of elderly patients. Pituitary adenomas (PAs) are one of those tumors whose incidence increases with age. Pituitary surgery in elderly has usually been considered riskier than in the younger population. The aim of this study was to evaluate the surgical outcome of a large series of patients who underwent transsphenoidal surgery for PAs.MethodsWe retrospectively reviewed a series of patients who underwent transsphenoidal surgery for PAs in our institution. Inclusion criteria were: 65 years of age or more, and no prev...
Source: Endocrine - Category: Endocrinology Source Type: research
Authors: Hozumi K, Fukuoka H, Odake Y, Takeuchi T, Uehara T, Sato T, Inoshita N, Yoshida K, Matsumoto R, Bando H, Hirota Y, Iguchi G, Taniguchi M, Otsuki N, Nishigori C, Kosaki K, Hasegawa T, Ogawa W, Takahashi Y Abstract Although acromegaly has been reported in patients with Neurofibromatosis type 1 (NF1), these cases have not been associated with growth hormone (GH)-producing somatotroph adenoma, but with optic pathway glioma. A 68 year-old Japanese woman, who had been clinically diagnosed with NF1, was referred to our hospital due to a thyroid tumor and hypercalcemia. Acromegaly was suspected due to her facial f...
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
This article discusses the diagnosis and treatment of patients with prolactinomas, acromegaly, Cushing disease, and other pituitary tumors during pregnancy.
Source: Endocrinology and Metabolism Clinics of North America - Category: Endocrinology Authors: Source Type: research
In this study, we evaluated the course of DTC in 14 acromegalic patients retrospectively. Fourteen papillary thyroid cancer patients without acromegaly, who were matched with the acromegalic patient group for age, gender and properties of thyroid cancer, were investigated as the control group. We identified no change in the course and treatment responses of DTC in association with the acromegaly activity, gender, age and disease duration, and all patients were found to be in remission for DTC at the time of investigation. Retrospective analysis of this cohort suggests that the activity of acromegaly may not affect the trea...
Source: Experimental and Clinical Endocrinology and Diabetes - Category: Endocrinology Authors: Tags: Article Source Type: research
Wenhua Feng Pasireotide is a multi-receptor ligand somatostatin analogue approved for medical treatment of Cushing’s disease and acromegaly. The liquid-phase total synthesis of pasireotide-a 18-membered cyclic hexapeptide-was achieved by the 3 + 2 + 1 strategy, and the Pro1-Phe6 peptide bond was selected as the final cyclization position. Two key fragments were simply synthesized using N,O-bis(trimethylsilyl)acetamide/N-hydroxysuccinimide ester (BSA/NHS) as coupling agents, and processes of the two key fragments were simple without any chromatographic purification. The current synthesis method is easily sca...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Resumen: La acromegalia es una enfermedad caracterizada por una desfiguraci ón somática de progresión lenta causada por la sobreproducción de hormona de crecimiento (GH) y factor de crecimiento insulinoide tipo 1 (IGF-1), predominantemente asociada con un adenoma hipofisario. La manifestación más evidente a nivel facial es un prognatismo mandibular por exceso de creci miento de la mandíbula. El propósito del presente trabajo fue realizar una comparación morfológica craneofacial mediante análisis cefalométrico y superposición cefalom&...
Source: Odontoestomatologia - Category: Dentistry Source Type: research
Condition:   Acromegaly Interventions:   Drug: IONIS GHR-LRx;   Drug: SRL Sponsor:   Ionis Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionOur analysis suggested that not only hormone control but also therapeutic regimens and presence of co-morbidities might affect QOL of patients with acromegaly in some dimensions.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
CONCLUSION: Our analysis suggested that not only hormone control but also therapeutic regimens and presence of co-morbidities might affect QOL of patients with acromegaly in some dimensions. PMID: 31147197 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - Category: General Medicine Authors: Tags: J Formos Med Assoc Source Type: research
More News: Acromegaly | Gastroenterology | Materials Science | Polyethylene Glycol | Sandostatin | Science | Study